User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse




Journal Article

Multiple event activation of a generic prodrug trigger by antibody catalysis

There are no MPG-Authors available
External Ressource
No external resources are shared
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available

Shabat, D., Rader, C., List, B., Lerner, R. A., & Barbas, C. F. (1999). Multiple event activation of a generic prodrug trigger by antibody catalysis. Proceedings of the National Academy of Sciences of the United States of America, 96(12), 6925-6930. doi:10.1073/pnas.96.12.6925.

Cite as: http://hdl.handle.net/11858/00-001M-0000-0014-A4EB-A
Chemotherapeutic regimes are typically limited by nonspecific toxicity. To address this problem we have developed a broadly applicable drug-masking chemistry that operates in conjunction with a unique broad-scope catalytic antibody. This masking chemistry is applicable to a wide range of drugs because it is compatible with virtually any heteroatom. We demonstrate that generic drug-masking groups may be selectively removed by sequential retro-aldol–retro-Michael reactions catalyzed by antibody 38C2. This reaction cascade is not catalyzed by any known natural enzyme. Application of this masking chemistry to the anticancer drugs doxorubicin and camptothecin produced prodrugs with substantially reduced toxicity. These prodrugs are selectively unmasked by the catalytic antibody when it is applied at therapeutically relevant concentrations. We have demonstrated the efficacy of this approach by using human colon and prostate cancer cell lines. The antibody demonstrated a long in vivo half-life after administration to mice. Based on these findings, we believe that the system described here has the potential to become a key tool in selective chemotherapeutic strategies.